Amgen (AMGN) Total Current Liabilities (2009 - 2026)

Amgen's Total Current Liabilities history runs 18 years deep, the most recent figure standing at $25.0 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 8.46% year-over-year to $25.0 billion; the TTM figure through Mar 2026 stood at $25.0 billion (up 8.46% YoY), while the FY2025 annual figure was $25.5 billion, up 10.35% from the prior year.
• Total Current Liabilities was $25.0 billion for Q1 2026 at Amgen, down from $25.5 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $25.5 billion in Q4 2025 to a low of $12.6 billion in Q2 2022.
• Historically, Total Current Liabilities has averaged $19.0 billion across 5 years, with a median of $19.7 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities fell 13.49% in 2022, then surged 38.68% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $15.7 billion in 2022, then rose by 17.24% to $18.4 billion in 2023, then increased by 25.59% to $23.1 billion in 2024, then grew by 10.35% to $25.5 billion in 2025, then dropped by 2.1% to $25.0 billion in 2026.
• The last three Total Current Liabilities figures came in at $25.0 billion (Q1 2026), $25.5 billion (Q4 2025), and $21.8 billion (Q3 2025), per Business Quant data.